The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00372372

Enrollment

120

Registered

2006-09-06

Start date

2004-01-31

Completion date

2007-04-30

Last updated

2007-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Keywords

corticosteroids, bone mineral, risedronate, bisphosphonate

Brief summary

The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment

Detailed description

We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases

Interventions

DRUGrisedronate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (\>=0.8mg/kg/day) or equivalent for at least 6 weeks. 2. Age\>=18 years and \<75 years.

Exclusion criteria

1. Pregnant or lactating women. 2. Uncorrected hypocalcemia. 3. History of esophageal stricture. 4. Previous intolerance or hypersenstivity to biphosphonates.

Design outcomes

Primary

Measure	Time frame
bone mineral density	—

Secondary

Measure	Time frame
Adverse events, new vertebral fractures	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026